SYNOVIAL TISSUE COLLECTION

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 在美国，关节炎是导致18岁及以上人群残疾的主要原因。关节炎引起的残疾给个人、他们的家庭、雇主和国家带来了巨大的医疗费用。事实上，疾病控制中心估计，每年与关节炎相关的医疗费用为150亿美元。目前可用的治疗方法在控制自身免疫性炎症性关节炎方面往往无效，如类风湿性关节炎和牛皮癣关节炎。了解引起和调节关节炎的机制对于开发新的、更好的和更具体的治疗方法至关重要。 类风湿性关节炎和银屑病关节炎的滑膜组织都具有高度侵袭性，导致软骨和骨骼破坏。滑膜组织收集计划的目的是从类风湿性关节炎、牛皮癣关节炎患者和对照组(接受创伤相关手术或骨关节炎的正常人)获取人类滑膜组织样本。这些组织对于鉴定差异表达的基因是必不可少的，这些基因可能解释了与疾病相关的侵袭性和破坏性行为。此外，将从这些组织中产生原代滑膜细胞系，并用于验证组织和体外功能研究中的基因表达结果。预计这些研究将确定新的治疗靶点。将使用这种材料进行的分析包括确定激活和侵袭状态的生化分析，以及微阵列实验。定量逆转录聚合酶链式反应和免疫组织化学将用于验证微阵列的结果。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Arthritis is the leading cause of disability in the United States in persons eighteen years and older. Disability arising from arthritic conditions accounts for tremendous health care costs for individuals, their families, employers, and the country. In fact, the Center for Disease Control estimated arthritis-related medical costs are $15 billion annually. Currently available therapies are often ineffective in controlling autoimmune inflammatory arthritis like rheumatoid arthritis and psoriatic arthritis. Understanding the mechanisms that cause and regulate arthritis is critical for the development of new, better and more specific therapies. Both rheumatoid arthritis and psoriatic arthritis synovial tissues have a highly invasive behavior that leads to cartilage and bone destruction. The purpose of the synovial tissue collection program is to obtain human synovial tissue samples from patients with rheumatoid arthritis, psoriatic arthritis and controls (normals undergoing trauma related surgery, or osteoarthritis). These tissues are essential for the identification of differentially expressed genes that may account for the disease-associated invasive and destructive behavior. Additionally, primary synovial cell lines will be generated from these tissues, and used to validate the gene expression findings from tissues, and well as in in vitro functional studies. It is anticipated that these studies will identify novel therapeutic targets. Assays that will be performed using this material include biochemical assays to determine the activation and invasive status, and microarray experiments. Quantitative reverse transcriptase polymerase chain reaction and immunohistochemistry will be used to validate the microarray findings.